NGM Biopharmaceuticals Inc
$
13.85
0.05 (0.36%)
| Volume: | 101,052 | Avg Vol (1m): | 70,576 |
| Market Cap $: | 914.40 Mil | Enterprise Value $: | 707.77 Mil |
| P/E (TTM): | 0.00 | P/B: | 3.99 |
| Earnings Power Value | 0 |
| Net Current Asset Value | 2.9 |
| Tangible Book | 3.48 |
| Projected FCF | 0 |
| Median P/S Value | 0 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
1Y (-%)
Manual of Stocks™ Web
Financial Strength : 8/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | No Debt |
Cash-To-Debt ranked
higher than
100.00%
of
1078
companies
in the
Biotechnology
industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
NGM:
No Debt
Ranked among companies with meaningful Cash-To-Debt only.
| N/A |
| Equity-to-Asset | 0.76 |
Equity-to-Asset ranked
higher than
100.00%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
NGM:
0.76
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: -0.49, Med: -0.42, Max: 0.76
Current: 0.76
|
| Interest Coverage | No Debt |
Interest Coverage ranked
higher than
100.00%
of
500
companies
in the
Biotechnology
industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
NGM:
No Debt
Ranked among companies with meaningful Interest Coverage only.
| N/A |
| Piotroski F-Score | 5 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 9.23 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.35 |
Not Manipulator
Manipulator
| |
Profitability & Growth : 2/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | -3.97 |
Operating Margin ranked
higher than
100.00%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
NGM:
-3.97
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -22.59, Med: -9.77, Max: -3.97
Current: -3.97
|
| Net Margin % | -0.45 |
Net Margin ranked
higher than
100.00%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
NGM:
-0.45
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -18.35, Med: -8.09, Max: -0.45
Current: -0.45
|
| ROE % | -1.50 |
ROE ranked
higher than
100.00%
of
989
companies
in the
Biotechnology
industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
NGM:
-1.5
Ranked among companies with meaningful ROE only.
| N/A |
| ROA % | -0.20 |
ROA ranked
higher than
100.00%
of
1084
companies
in the
Biotechnology
industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
NGM:
-0.2
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -5.38, Med: -2.5, Max: -0.2
Current: -0.2
|
| ROC (Joel Greenblatt) % | -17.14 |
ROC (Joel Greenblatt) ranked
higher than
100.00%
of
1036
companies
in the
Biotechnology
industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
NGM:
-17.14
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -66.93, Med: -30.75, Max: -17.14
Current: -17.14
|
» NGM's 30-Y Financials
Financials (Next Earnings Date: 2019-08-15)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:NGM
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology NAICS : 325414 SIC : 2836 |
| Compare | |
| Traded in other countries | 0IK.Germany |
| Address | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PB Ratio | 3.99 |
PB Ratio ranked
higher than
100.00%
of
962
companies
in the
Biotechnology
industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
NGM:
3.99
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 0, Med: 0, Max: 6.42
Current: 3.99
|
| PS Ratio | 6.82 |
PS Ratio ranked
higher than
100.00%
of
726
companies
in the
Biotechnology
industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
NGM:
6.82
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 0, Med: 0, Max: 6.94
Current: 6.82
|
| EV-to-EBIT | -164.06 |
EV-to-EBIT ranked
higher than
100.00%
of
261
companies
in the
Biotechnology
industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
NGM:
-164.06
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -230.22, Med: 0, Max: 0
Current: -164.06
|
| EV-to-EBITDA | 243.33 |
EV-to-EBITDA ranked
higher than
100.00%
of
281
companies
in the
Biotechnology
industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
NGM:
243.33
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: 0, Med: 0, Max: 341.4
Current: 243.33
|
| EV-to-Revenue | 6.50 |
EV-to-Revenue ranked
higher than
100.00%
of
771
companies
in the
Biotechnology
industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
NGM:
6.5
Ranked among companies with meaningful EV-to-Revenue only.
| N/A |
| Current Ratio | 5.17 |
Current Ratio ranked
higher than
100.00%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
NGM:
5.17
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 4.76, Med: 5.17, Max: 6.23
Current: 5.17
|
| Quick Ratio | 5.17 |
Quick Ratio ranked
higher than
100.00%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
NGM:
5.17
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 4.76, Med: 5.17, Max: 6.23
Current: 5.17
|
Dividend & Buy Back
| Current | vs industry | vs history |
|---|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 3.98 |
Price-to-Tangible-Book ranked
higher than
100.00%
of
894
companies
in the
Biotechnology
industry.
Industry Max: 800, Med: 5.32, Min: 0.05
NGM:
3.98
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 0, Med: 0, Max: 4.05
Current: 3.98
|
| Earnings Yield (Joel Greenblatt) % | -0.59 |
Earnings Yield (Greenblatt) ranked
higher than
100.00%
of
1081
companies
in the
Biotechnology
industry.
Industry Max: 5000, Med: -7.73, Min: -10000
NGM:
-0.59
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -0.69, Med: 0, Max: 0
Current: -0.59
|
More Statistics
| Revenue (TTM) (Mil) $ | 108.67 |
| EPS (TTM) $ | -0.01 |
| Beta | 0 |
| Volatility % | 0 |
| 52-Week Range $ | 12 - 18.75 |
| Shares Outstanding (Mil) | 66.02 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 5 |
| Positive ROA | N |
| Positive CFROA | N |
| Higher ROA yoy | Y |
| CFROA > ROA | N |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | Y |
| Higher Gross Margin yoy | N |
| Higher Asset Turnover yoy | Y |